실시간
Clinical OMICsGLP-1 Drugs Lower Risk of Death by 44% in Obesity and Autoimmune DiseaseCellDeep-sea megafauna co-opts microbial energy metabolism genes to withstand ultra-long starvationCellReplaying germinal center evolution on a quantified affinity landscapeCellXenophagocytosis blockade enhances interspecies chimerismFierceBiotechADA: Pfizer pads case for berobenatide in obesity, adding validation to Metsera buyEndpoints News#ADA26: Pfizer monthly shot shows effect on obesity, diabetesEndpoints News#ADA26: Roche to start Phase 2 petrelintide, enicepatide combo trial this yearEndpoints NewsLawmakers propose China restrictions; #ASCO26 recap; and moreFierceBiotech‘It looks like this hypothesis will pan out’: Cullinan unveils data building case for autoimmune TCEsAmgenAmgen: A Biotech Giant's Path to Recovery and Growth - AOL.comAmgenAmgen: A Biotech Giant's Path to Recovery and Growth - The Motley Fool
Illumina 2025년 12월 15일

Illumina (NASDAQ:ILMN) Given New $130.00 Price Target at JPMorgan Chase & Co. - MarketBeat

Illumina (NASDAQ:ILMN) Given New $130.00 Price Target at JPMorgan Chase & Co. - MarketBeat

본문을 이용할 수 없습니다. 원본 출처를 확인하세요.